Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Generic Name: Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）

Indication: 用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；

2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；

3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；

4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；

5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。

Clinical Trials

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

Phase 2

Completed

Conditions: Uveal Melanoma
Liver Metastases

Interventions: Drug: GM-CSF
Procedure: Embolization

First Posted Date: 2008-04-18

Last Posted Date: 2025-05-16

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 53

Registration Number: NCT00661622

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Biological: INKT
Drug: GM-CSF

First Posted Date: 2008-03-07

Last Posted Date: 2017-06-09

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 9

Registration Number: NCT00631072

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Phase 2

Completed

Conditions: Malignant Melanoma

First Posted Date: 2008-02-15

Last Posted Date: 2012-05-03

Lead Sponsor: Mt. Sinai Medical Center, Miami

Target Recruit Count: 36

Registration Number: NCT00616564

Locations: 🇺🇸
Jose Lutzky, MD, Miami Beach, Florida, United States
🇺🇸
David Lawson, MD, Atlanta, Georgia, United States

Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

Interventions: Biological: therapeutic autologous lymphocytes
Genetic: Use of an artificial antigen presenting cell (aAPC) to generate CTL
Drug: GM-CSF
Radiation: Irradiation of cutaneous tumor lesion

First Posted Date: 2007-08-08

Last Posted Date: 2013-03-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 9

Registration Number: NCT00512889

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Campath-1H
Drug: G-CSF
Drug: GM-CSF
Drug: BCNU
Drug: Stem Cell Transplant
Drug: Preparative Regimen for Allogenic Stem Cell Transplantation
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Campath
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Low dose total body irradiation

First Posted Date: 2007-07-25

Last Posted Date: 2011-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00505921

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Cancer

Interventions: Drug: Carboplatin
Drug: GM-CSF (Sargramostim)
Drug: Interferon Gamma

First Posted Date: 2007-07-16

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT00501644

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Etoposide
Drug: G-CSF
Drug: GM-CSF
Drug: Isophosphamide
Drug: Rituximab
Procedure: Apheresis

First Posted Date: 2007-07-11

Last Posted Date: 2013-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 84

Registration Number: NCT00499343

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)
Chronic Myeloid Leukemia (CML)
Myelodysplastic Syndrome (MDS)

Interventions: Drug: GM-CSF (Sargramostim)
Biological: Montanide adjuvant

First Posted Date: 2007-06-20

Last Posted Date: 2021-07-12

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 10

Registration Number: NCT00488592

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Phase 2

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: Mitoxantrone
Drug: GM-CSF

First Posted Date: 2007-05-22

Last Posted Date: 2017-11-29

Lead Sponsor: Stanford University

Target Recruit Count: 10

Registration Number: NCT00477087

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Diffuse

Interventions: Drug: GM-CSF
Drug: CHOP
Drug: Rituximab

First Posted Date: 2007-04-04

Last Posted Date: 2018-01-18

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 3

Registration Number: NCT00455897

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy